Basic information Safety Supplier Related

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE

Basic information Safety Supplier Related

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Basic information

Product Name:
1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE
Synonyms:
  • NO-711 HYDROCHLORIDE
  • NNC 711
  • 1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE
  • 1-(2-(((DIPHENYLMETHYLENE)IMINO)OXY)ETHYL)-1,2,5,6-TETRAHYDRO-3-PYRIDINE CARBOXYLIC ACID HYDROCHLORIDE
  • NO-711 HCL POTENT GABA UPTAKE IN
  • 1,2,5,6-Tetrahydro-1-(2-(((diphenylmethylene)amino)oxy]ethyl)-3-pyridinecarboxylicacidhydrochloride
  • NNC711,HCl
  • 1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride
CAS:
145645-62-1
MF:
C21H23ClN2O3
MW:
386.87
Product Categories:
  • GABA/Glycine receptor
Mol File:
145645-62-1.mol
More
Less

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Chemical Properties

storage temp. 
protect from light
solubility 
H2O: ≥10 mg/mL at 60 °C
form 
solid
color 
off-white
Water Solubility 
H2O: 10mg/mL at60°C
More
Less

Safety Information

WGK Germany 
3

MSDS

More
Less

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE Usage And Synthesis

Uses

NNC 711 is an anticonvulsant agent and a selective GABA uptake inhibitor (1,2).

Uses

NO-711 hydrochloride is suitable for use as γ-aminobutyric acid (GABA) transporter-1 (GAT-1) antagonists or GABA uptake inhibitor.

Biological Activity

Potent and selective inhibitor of GABA uptake by GAT-1 (IC 50 values are 0.04, 171, 1700 and 622 μ M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo .

Biochem/physiol Actions

NO-711 is a potent and selective GABA uptake inhibitor that crosses the blood-brain barrier.

in vivo

NNC-711 (0.25-3 mg/kg; i.p.; 30 min prior to training) prevents amnesia for a passive avoidance task induced by the acetylcholine receptor antagonist Scopolamine (HY-N0296) in male Wistar rat[2].
NNC-711 (0.5-3 mg/kg; i.p.; immediately prior to occlusion) protects against ischemia-induced death of CA1 pyramidal neurons in a model of bilateral common carotid artery occlusion in the gerbil[2].
NNC-711 (0.5-1.5 mg/kg; i.p.; immediately prior to training) exhibits significant cognition-enhancing actions in postnatal day 80 male and 28-month old female Wistar rats[2].
NNC-711 (NO-711) (50-200 μg/10 μL; i.t.; once) effectively develops analgesic effect in sciatic nerve CCI rats modelc[3].
NNC-711 (0.3-30 mg/kg, i.p.; 30 min before testing) exhibits anticonvulsant effects in Multiple mices and rats epilepsy model[4].

Animal Model:DMCM (HY-100369A)-induced seizures in female NMRI mice (20 g), pentylenetetrazole-induced seizures in male NMRI mice and male albino Wistar SPF rats (150-200 g), Audiogenic seizures in male DBA/2 mice (8 g) [4]
Dosage:0.3-30 mg/kg
Administration:Intraperitoneal injection (i.p.); 30 min prior to the seizure test
Result:Inhibited DMCM-induced clonic seizures in NMRI mice with an ED50 = 1.2 mg/kg.
Animal Model:Postnatal day 80 male Wistar rats (300-350 g)[2]
Dosage:0.25, 0.5, 1, 3 mg/kg
Administration:Intraperitoneal injection (i.p.); 30 min prior to training
Result:Significantly reversed the amnesia induced by scopolamine administration 6-h post-training when retrieval was tested at 24-h post-training.
Had no effect on learning in the 0.25-0.5 mg/kg dose range, and induced amnesia at 3.0 mg/kg.
Not to directly interact with the cholinergic system, but rather to have a more general neuroprotective action on the consolidation process.
Animal Model:Postnatal day 80 male Mongolian gerbils (50-65 g)[2]
Dosage:0.5, 3 mg/kg
Administration:Intraperitoneal injection (i.p.); immediately prior to occlusion
Result:Administrated immediately prior to occlusion significantly reduced CA1 cell death.
Animal Model:Postnatal day 80 male Wistar rats (300-350 g) and 28-month old female Wistar rats[2]
Dosage:0.5, 1.5 mg/kg
Administration:Intraperitoneal injection (i.p.); immediately prior to training
Result:Significantly reduced escape latencies in both mature postnatal day 80 and aged 28 months rats.
Improved rats ability to locate the hidden platform at 0.5 mg/kg, but the effect was reduced at 1.5 mg/kg.
Had no effect on memory retention.
Animal Model:Sciatic nerve chronic constriction injury (CCI) rats[3]
Dosage:50, 100, 200 μg/10 μL
Administration:Intrathecal (i.t.); once
Result:Increased withdrawal thresholds (WT) and withdrawal latency (WL) values after 1 day compared with CCI + saline group.
The maximum value of WT was achieved 3 days after administration and maximum value of WL was achieved 1 day after administration.

storage

Desiccate at +4°C

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDESupplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
EMMX Biotechnology LLC
Tel
888-539-0666
Email
info@emmx.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
BOC Sciences
Tel
Email
info@bocsci.com
More
Less

1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE(145645-62-1)Related Product Information